

ORIGINAL RESEARCH

Combined Evaluation of Arterial Stiffness and Blood Pressure Promotes Risk Stratification of Peripheral Arterial Disease



Zhiyuan Wu, BD,^{a,b,*} Yue Jiang, BD,^{a,*} Qian Zhu, BD,^a Haiping Zhang, BD,^a Zhiwei Li, BD,^a Jinqi Wang, BD,^a Huiying Pan, BD,^a Zheng Guo, BD,^b Yulu Zheng, MD,^b Xia Li, PhD,^c Lixin Tao, PhD,^a Bo Gao, PhD,^a Xiuhua Guo, PhD^{a,b}

ABSTRACT

BACKGROUND Previous studies have reported the separate association of arterial stiffness (AS) and blood pressure with peripheral arterial disease (PAD).

OBJECTIVES The aim of this study was to investigate the risk stratification capacity of AS on incident PAD beyond blood pressure status.

METHODS A total of 8,960 participants from Beijing Health Management Cohort were enrolled at the first health visit between 2008 and 2018 and then followed until the incidence of PAD or 2019. Elevated AS was defined as brachial-ankle pulse-wave velocity (baPWV) >1,400 cm/s, including moderate stiffness (1,400 ≤ baPWV <1,800 cm/s) and severe stiffness (baPWV ≥1,800 cm/s). PAD was defined as ankle-brachial index <0.9. A frailty Cox model was used to calculate the HR, integrated discrimination improvement, and net reclassification improvement.

RESULTS During follow-up, 225 participants (2.5%) developed PAD. After adjusting for confounding factors, the highest risk for PAD was observed in the group with elevated AS and blood pressure (HR: 2.253; 95% CI: 1.472-3.448). Among participants with ideal blood pressure and those with well-controlled hypertension, PAD risk was still significant for severe AS. The results remained consistent in multiple sensitivity analyses. In addition, baPWV significantly improved the predictive capacity for PAD risk beyond systolic and diastolic blood pressures (integrated discrimination improvement 0.020 and 0.190, net reclassification improvement 0.037 and 0.303).

CONCLUSIONS This study suggests the clinical importance of combined evaluation and control of AS and blood pressure for the risk stratification and prevention of PAD. (JACC: Asia 2023;3:287-297) © 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis¹ that occurs most frequently in the arteries of the lower extremity. It is estimated that globally, approximately 202 million people have PAD.² Ankle-brachial index (ABI) is a primary noninvasive test to diagnose lower extremity PAD. In healthy subjects, ABI is >1.0, whereas ABI <0.9 is commonly used to

From the ^aBeijing Municipal Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China; ^bCentre for Precision Health, Edith Cowan University, Perth, Australia; and the ^cDepartment of Mathematics and Statistics, La Trobe University, Melbourne, Australia. *Drs Wu and Jiang analyzed the data and drafted the paper together. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received August 30, 2022; revised manuscript received February 6, 2023, accepted February 7, 2023.

**ABBREVIATIONS
AND ACRONYMS****ABI** = ankle-brachial index**AS** = arterial stiffness**baPWV** = brachial-ankle pulse-wave velocity**DBP** = diastolic blood pressure**HDL** = high-density lipoprotein**HTAS** = hypertension with elevated arterial stiffness**HTMAS** = hypertension with moderately elevated arterial stiffness**HTNAS** = hypertension with normal arterial stiffness**HTSAS** = hypertension with severely elevated arterial stiffness**NHTNAS** = no hypertension with normal arterial stiffness**PAD** = peripheral arterial disease**SBP** = systolic blood pressure

diagnose PAD, with estimated diagnostic sensitivity and specificity of 79% and 96%, respectively.³ Prevalent PAD significantly increases the risk for cardiovascular events and overall death.^{4,5}

Studies have shown that people with smoking behavior, hypertension, diabetes, and obesity have a higher prevalence of PAD and a significantly increased risk for adverse cardiovascular events.⁶⁻⁸ A study revealed that reduced high-density lipoprotein (HDL) cholesterol is significantly associated with a higher risk for cardiovascular events and mortality in patients with PAD.⁹ These findings indicate that there are shared risk factors between PAD and cardiovascular diseases. Arterial stiffness (AS) measured at the material or structural level is an important surrogate marker of vascular damage and a strong predictor of cardiovascular disease.¹⁰ Degenerative changes in the intima of large elastic arteries contribute to the loss of arterial elastin and increase of AS. Although most

sensitive to effects of blood pressure and aging, AS provides significant clinical value independently.^{11,12} In a cross-sectional analysis, AS was independently associated with PAD even when adjusting for several atherosclerotic risk factors, including age.¹³ A cohort study reported the relationship between blood pressure parameters and PAD events.¹⁴ AS was also reported to affect the prognosis of patients with PAD.¹⁵ However, the combined effect of AS and blood pressure on incident PAD remains unknown. A recent study revealed that AS status could better predict diabetes onset than hypertension.¹⁶ No study has focused on whether AS could be a risk enhancer for PAD independent of blood pressure.

Therefore, in this study we aimed to explore the combined association of AS and hypertension status with PAD onset using a Chinese cohort and to reveal the clinical importance of joint assessment of AS and blood pressure for the risk stratification and primary prevention of PAD.

METHODS

STUDY POPULATION. Subjects for the present study were recruited from the Beijing Health Management Cohort. Participants underwent annual examinations, including face-to-face questionnaire surveys, physical examinations, and laboratory blood tests, as described in a previous publication.¹⁷

The present study included 10,632 participants who participated in the health examinations and AS measurements for the first time between 2008 and 2018 and were then followed until the onset of PAD or the end of 2019. We excluded participants with missing data for brachial-ankle pulse-wave velocity (baPWV) or ABI at baseline (n = 1,038). In addition, participants with PAD at baseline (n = 126), self-reported cardiovascular disease (n = 354), age <20 years (n = 2), or missing blood pressure information (n = 152) were also excluded (Figure 1). This study was in accordance with the principles of the Declaration of Helsinki and approved by the ethics committee of Capital Medical University (2020SY031). All participants provided written informed consent before taking part in this study.


BLOOD PRESSURE MEASUREMENT AND HYPERTENSION DEFINITION.

Blood pressure was measured in a sitting position using a mercury sphygmomanometer, and the average of 2 measurements was recorded using systolic blood pressure (SBP) and diastolic blood pressure (DBP). The correlation coefficients between the 2 measurements were 0.988 for SBP and 0.976 for DBP. The difference between the 2 measurements should be <10 mm Hg. Mean arterial blood pressure was calculated as: (SBP + 2 × DBP) / 3. Hypertension was defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg, use of any antihypertensive medication, or self-reported history of diagnosed hypertension.

BaPWV MEASUREMENT AND AS DEFINITION.

BaPWV was measured using the Colin BP-203RPE III device (Omron Healthcare). After the patient lay supine for 5 minutes, 4 cuffs were placed on the bilateral brachial and ankle joints, and then the plethysmographic sensor and the oscilloscope pressure sensor were connected, and the maximum value of baPWV on the left and right sides was selected as the systemic AS level, as previously described.^{18,19} Normal AS was defined as baPWV <1,400 cm/s and elevated AS as baPWV ≥1,400 cm/s. In addition, we also classified baPWV into 3 categories: normal AS was defined as baPWV <1,400 cm/s, moderately elevated AS as 1,400 ≤ baPWV <1,800 cm/s, and severely elevated AS as baPWV ≥1,800 cm/s according to previous standards.^{20,21}

ABI MEASUREMENT AND PAD DEFINITION. ABI is the ratio of blood pressure in the ankle arteries to that in the brachial arteries on the same side of the subject. Using the Colin BP-203RPE III device, the upper limbs and ankles were fully exposed in the supine position, and the subject's bilateral humeral and



ankle arterial SBPs were measured simultaneously; the software then automatically calculated the ABI according to the aforementioned formula. PAD was defined as ABI <0.9 in either lower limb.^{22,23} The included participants were free of PAD at baseline and annually followed for PAD onset.

COVARIATES MEASUREMENT AND DEFINITION.

Information on age, sex, education, physical activity, smoking status, drinking status, and disease history were collected using a standard questionnaire (Supplemental Appendix). Educational level was categorized as “primary education,” “secondary education,” and “third education.” Physical activity was defined as “≥80 minutes of moderate or vigorous physical activity per week.” Smoking status was divided into “current smoking” and “no current smoking” during the past year. Drinking status was divided into “current drinking” and “no current drinking” during the past year. Disease history included self-reported cardiovascular diseases, hypertension, and diabetes. Physical examination parameters included height, weight, heart rate, and waist circumference. Body

mass index was calculated as weight (kilograms) divided by the square of height (meters). Biochemical parameters included fasting blood glucose, triglycerides, total cholesterol, HDL cholesterol, and low-density lipoprotein cholesterol. Fasting glucose was defined as glucose concentration before breakfast after overnight fasting (no intake, except water, for at least 8 hours). Diabetes was defined as fasting glucose ≥7.0 mmol/L, self-reported history of diabetes, or self-reported use of antidiabetic medication.

STATISTICAL ANALYSIS.

Participants were divided into 4 groups according to joint hypertension and AS status at baseline: 1) no hypertension with normal AS (NHTNAS); 2) no hypertension with elevated AS; 3) hypertension with normal AS (HTNAS); and 4) hypertension with elevated AS (HTAS). Considering the severity of AS, baPWV was classified into 3 categories, and participants were correspondingly divided into 6 groups together with hypertension status (Supplemental Figure 1): 1) NHTNAS; 2) no hypertension with moderately elevated AS; 3) no hypertension with severely elevated AS;

TABLE 1 Baseline Characteristics of the Study Population (N = 8,960)

Age, y	53.41 ± 13.35
Range	22-94
Age group	
≤44 y	2,257 (25.2)
45-59 y	4,293 (47.9)
≥60 y	2,410 (26.9)
Male	2,501 (27.9)
Educational level	
Primary	1,196 (13.3)
Secondary	5,810 (64.8)
Third	1,954 (21.8)
Physical activity	4,228 (47.2)
Current smoking	2,563 (28.6)
Current drinking	5,891 (65.7)
BMI, kg/m ²	25.5 (23.5-27.6)
Obese	1,824 (21.0)
Overweight	6,056 (69.6)
Waist circumference, cm	88.0 (81.0-94.0)
Heart rate, beats/min	76.0 (69.0-84.0)
MAP, mm Hg	108.7 (98.7-118.3)
LDL cholesterol, mmol/L	3.1 (2.5-3.7)
Triglycerides, mmol/L	1.4 (1.0-2.0)
HDL cholesterol, mmol/L	1.2 (1.1-1.4)
Total cholesterol, mmol/L	4.9 (4.3-5.5)
Fasting glucose, mmol/L	5.4 (5.0-5.9)
Serum uric acid, μmol/L	349.0 (294.0-407.0)
Hypertension	2,617 (29.2)
Use of antihypertensive medication	612 (6.8)
Diabetes	999 (11.1)
Use of hypoglycemic medication	180 (2.0)
ABI, median (range)	1.12 (0.91-1.39)
Ankle blood pressure, mm Hg	139.2 (125.0-155.2)

Values are mean ± SD, n (%), or median (IQR), except as indicated.
ABI = ankle-brachial index; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MAP = mean arterial pressure.

4) HTNAS; 5) hypertension with moderately elevated AS (HTMAS); and 6) hypertension with severely elevated AS (HTSAS). The incidence rate was calculated as the number of incident cases divided by the total follow-up duration (person-years). The cumulative incidence rate was defined as the number of incident cases divided by the total number of participants.

We used the frailty Cox proportional hazards regression models to analyze the risk for PAD across groups. To solve the existence of tied events due to annual follow-up, the Efron method was used in the Cox model. Some participants were from the same working place, which was considered a random term in the frailty Cox model. HRs with 95% CIs were calculated using the NHTNAS group as the reference.


Model 1 was unadjusted; model 2 was adjusted for age group, sex, educational level, physical activity, smoking status, and drinking status; and model 3 was further adjusted for body mass index, heart rate, total cholesterol, HDL cholesterol, fasting glucose, and serum uric acid.

We performed several sensitivity analyses to validate the observed results. First, hypertension was redefined as SBP ≥130 mm Hg, DBP ≥80 mm Hg, use of any antihypertensive medication, or self-reported history of diagnosed hypertension. Second, we excluded participants who developed PAD within the first year of follow-up. Third, we performed analyses on the complete data and multiple imputed datasets (5 iterations) using Markov-chain Monte Carlo. Fourth, we repeated analyses after excluding participants using any antihypertensive medication.

In subgroup analyses, the hypertensive population was divided into a poorly controlled group and a well-controlled group (defined as SBP <140 mm Hg and DBP <80 mm Hg among patients with hypertension).¹⁶ The effect of AS on PAD was then analyzed using the NHTNAS group as a reference. In addition, we analyzed the incremental predictive capacity of baPWV level beyond blood pressure using the C index, integrated discrimination improvement, and continuous net reclassification index, which does not require discrete risk categories and relies on the proportions of individuals with outcome correctly assigned a higher probability and individuals without outcome correctly assigned a lower probability by an updated model compared with the initial model.²⁴ Integrated discrimination improvement and net reclassification improvement >0 indicates a positive improvement of the original model.²⁵ All statistical analyses were performed using R version 4.1.0 (R Foundation for Statistical Computing), and a 2-sided *P* value <0.05 was considered to indicate statistical significance.

RESULTS

BASILINE CHARACTERISTICS. Table 1 shows the baseline characteristics of the 8,960 participants. The mean age of the population is 53.41 ± 13.35 years. There were 4,293 participants (47.9%) between 45 and 59 years of age, and 2,501 were men (27.9%). The median ABI at baseline was 1.12, ranging from 0.91 to 1.39. The median value of ankle blood pressure was 139.2 mm Hg (IQR: 125.0-155.2 mm Hg). Characteristics according to joint hypertension and AS status (4 groups) are shown in Supplemental Table 1, and



people in the HTAS group were older, with higher waist circumference, heart rate, mean arterial pressure, and fasting glucose. [Supplemental Table 2](#) shows baseline characteristics according to the 6 groups by hypertension status and AS severity.

COMBINED HYPERTENSION AND AS STATUS WITH PAD ONSET. During follow-up, a total of 225 cases of PAD occurred. Participants in the HTAS group had the highest risk for developing PAD (log-rank $P < 0.0001$) ([Figure 2](#)). The incidence rates were 3.12, 2.71, 7.64, and 14.05 per 1,000 person-years for the NHTNAS, HTNAS, no hypertension with elevated AS, and HTAS groups, respectively ([Supplemental Table 3](#)). In addition, people with severe AS had the highest incidence rate of PAD, regardless of hypertension and

blood pressure control status ([Supplemental Table 4](#), [Supplemental Figure 2](#)).

After adjusting for confounding factors, the HR for incident PAD was 2.253 (95% CI: 1.472-3.448) for the HTAS group compared with the NHTNAS group, and the remaining 2 groups were not statistically significant. No significant interaction effect of hypertension and AS was observed (P for interaction = 0.700). Among participants without hypertension, the HR was 2.286 (95% CI: 1.288-4.058) for severely elevated AS. In those with hypertension, the HRs were 1.887 (95% CI: 1.173-3.036) and 3.150 (95% CI: 1.942-5.108) for both moderately elevated AS (HTMAS) and severely elevated AS (HTSAS), as shown in [Table 2](#). The

TABLE 2 Association of Combined AS and Hypertension Status With Risk for Peripheral Arterial Disease

	Model 1		Model 2		Model 3	
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Classification 1						
No hypertension/normal AS (39 of 4,057)	Reference	—	Reference	—	Reference	—
None hypertension/elevated AS (67 of 2,286)	2.672 (1.800-3.968)	<0.001	1.345 (0.874-2.070)	0.178	1.321 (0.853-2.046)	0.213
Hypertension/normal AS (5 of 559)	0.886 (0.349-2.249)	0.800	0.841 (0.331-2.136)	0.715	0.719 (0.256-2.021)	0.531
Hypertension/elevated AS (114 of 2,058)	4.959 (3.444-7.140)	<0.001	2.236 (1.484-3.371)	<0.001	2.253 (1.472-3.448)	<0.001
Classification 2						
No hypertension/normal AS (39 of 4,057)	Reference	—	Reference	—	Reference	—
No hypertension/moderate AS (42 of 1,929)	2.004 (1.295-3.100)	0.002	1.201 (0.753-1.914)	0.442	1.185 (0.738-1.903)	0.482
No hypertension/severe AS (25 of 357)	6.150 (3.719-10.168)	<0.001	2.307 (1.312-4.055)	0.004	2.286 (1.288-4.058)	0.005
Hypertension/normal AS (5 of 559)	0.887 (0.350-2.250)	0.800	0.841 (0.331-2.136)	0.715	0.716 (0.255-2.013)	0.526
Hypertension/moderate AS (45 of 1316)	3.129 (2.037-4.807)	<0.001	1.853 (1.169-2.934)	0.009	1.887 (1.173-3.036)	0.009
Hypertension/severe AS (69 of 742)	8.067 (5.441-11.962)	<0.001	3.118 (1.955-4.972)	<0.001	3.150 (1.942-5.108)	<0.001

The reference group was defined as no hypertension with normal AS (baPWV <1,400 cm/s). Elevated AS was defined as baPWV ≥1,400 cm/s, moderate AS as 1,400 ≤ baPWV <1,800 cm/s, and severe AS as baPWV ≥1,800 cm/s. Classification 1 was stratified by hypertension status and AS status. Classification 2 was stratified by hypertension status and the severity of AS. Model 1 was unadjusted; model 2 was adjusted for age group, sex, educational level, physical activity, smoking status, and alcohol status; and model 3 was further adjusted for body mass index, heart rate, total cholesterol, high-density lipoprotein cholesterol, fasting glucose and serum uric acid.

AS = arterial stiffness; baPWV = brachial-ankle pulse-wave velocity.

results remained consistent when using alternative definitions of hypertension (Supplemental Table 5) and in multiple sensitivity analyses (Supplemental Table 6). In addition, people with hypertension and elevated AS had the severest ABI progression, as shown in Supplemental Table 7.

SUBGROUP ANALYSIS STRATIFIED BY BLOOD PRESSURE CONTROL STATUS. Among participant with well-controlled hypertension, the HRs for the HTAS and HTSAS groups were 2.331 (95% CI: 1.140-4.767) and 5.689 (95% CI: 2.276-14.220), respectively, compared with the NHTNAS group. Of note, among participant with poorly controlled hypertension, the HR for the HTAS, HTMAS, and HTSAS group were significant at 2.584 (95% CI: 1.626-4.108), 2.213 (95% CI: 1.335-3.668), and 3.358 (95% CI: 1.958-5.760), respectively. On the contrary, people with normal AS had similar risk compared with those in the NHTNAS group, regardless of blood pressure control status (Table 3). The results remained consistent when using alternative definitions of hypertension (Supplemental Table 8).

INCREMENTAL PREDICTIVE CAPACITY OF AS ASSESSMENT. BaPWV level significantly improved the predictive capacity of incident PAD. The C-index values for separate SBP and DBP for predicting PAD onset were 0.654 (95% CI: 0.607-0.702) and 0.579 (95% CI: 0.530-0.628) and increased to 0.692 (95% CI: 0.646-0.739) and 0.691 (95% CI: 0.643-0.739) with additional AS assessment. The integrated

discrimination improvement and net reclassification improvement were 0.020 (95% CI: 0.009-0.038) and 0.037 (95% CI: 0.021-0.061) for SBP and 0.190 (95% CI: 0.096-0.258) and 0.303 (95% CI: 0.214-0.383) for DBP (Figure 3). In addition, we found that baPWV and blood pressure levels outperformed baseline ABI for predicting PAD events (Supplemental Figure 3).

DISCUSSION

In this prospective study, we found that participants with elevated AS and hypertension had the highest risk for incident PAD, as summarized in the Central Illustration. Among people with ideal blood pressure and the population with well-controlled hypertension, assessment of AS still significantly contributed to the risk stratification of PAD onset. In addition, AS assessment significantly improved the predictive capacity for incident PAD.

ABI is an indicator of arterial stenosis and obstruction in the lower extremities.²⁶ ABI has good sensitivity and excellent specificity in detecting PAD.²⁷ ABI is an independent risk factor for the development of cardiovascular diseases and all-cause mortality.^{28,29} AS is an indicator of structural and functional changes in vessel walls, causing thickening of artery walls, reduced complacency, and increased rigidity.³⁰ Previous studies have shown that elevated AS is associated with an increased risk for cardiovascular events such as coronary artery disease, stroke, and end-stage renal disease.^{31,32} Husmann


TABLE 3 AS and Peripheral Arterial Disease Stratified by Blood Pressure Control Status in Patients With Hypertension

	Model 1		Model 2		Model 3	
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Reference group (39 of 4,057)	Reference	–	Reference	–	Reference	–
Well-controlled hypertension						
Normal AS ^a (0 of 173)		–		–		–
Elevated AS (16 of 328)	4.365 (2.429-7.845)	<0.001	2.549 (1.253-5.186)	0.010	2.331 (1.140-4.767)	0.020
Moderate AS (5 of 237)	1.897 (0.746-4.825)	0.179	1.338 (0.490-3.656)	0.570	1.210 (0.441-3.323)	0.711
Severe AS (11 of 91)	10.746 (5.477-21.085)	<0.001	6.042 (2.457-14.859)	<0.001	5.689 (2.276-14.220)	<0.001
Poorly controlled hypertension						
Normal AS (5 of 386)	1.313 (0.517-3.330)	0.567	1.266 (0.498-3.218)	0.620	1.060 (0.375-3.002)	0.912
Elevated AS (98 of 1,730)	5.143 (3.545-7.463)	<0.001	2.660 (1.718-4.118)	<0.001	2.584 (1.626-4.108)	<0.001
Moderate AS (40 of 1,079)	3.460 (2.225-5.382)	<0.001	2.274 (1.407-3.675)	0.001	2.213 (1.335-3.668)	0.002
Severe AS (58 of 651)	7.787 (5.180-11.708)	<0.001	3.460 (2.071-5.782)	<0.001	3.358 (1.958-5.760)	<0.001

The reference group was defined as no hypertension with normal AS (baPWV <1,400 cm/s). Elevated AS was defined as baPWV ≥1,400 cm/s, moderate AS as 1,400 ≤ baPWV <1,800 cm/s, and severe AS as baPWV ≥1,800 cm/s. Model 1 was unadjusted; model 2 was adjusted for age group, sex, educational level, physical activity, smoking status, and alcohol status; and model 3 was further adjusted for body mass index, heart rate, total cholesterol, high-density lipoprotein cholesterol, fasting glucose, and serum uric acid. ^aNo participant developed peripheral arterial disease in this group.

Abbreviations as in Table 2.


FIGURE 3 Predictive Capacity of Blood Pressure and Arterial Stiffness Assessments



B

	C-index		IDI		NRI	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
SBP	0.654***	0.607 – 0.702				
DBP	0.579***	0.530 – 0.628				
SBP+baPWV ^a	0.692***	0.646 – 0.739	0.020***	0.009 – 0.038	0.190***	0.096 – 0.258
DBP+baPWV ^b	0.691***	0.643 – 0.739	0.037***	0.021 – 0.061	0.303***	0.214 – 0.383

(A) C-index values for predicting peripheral artery disease at different follow-up times. (B) Incremental predictive capacity of arterial stiffness beyond blood pressure. Statistical significance was calculated using the DeLong test for C-index comparison and bootstrap for integrated discrimination improvement (IDI) and continuous net reclassification improvement (NRI) comparison. ***P < 0.001 (^acompared with model of systolic blood pressure [SBP], ^bcompared with model of diastolic blood pressure [DBP]). baPWV = brachial-ankle pulse-wave velocity.



et al³³ suggested that arterial lumen narrowing and severe ischemia, as late manifestations of PAD, may be regarded as the end stage of increased AS. Two cross-sectional studies showed that patients with PAD had greater AS.^{13,34} Moreover, elevated AS may be an indicator of high mortality in patients with PAD with claudication or severe ischemia.³⁵ On the contrary, a study in middle-aged Japanese men free of PAD reported that decreased AS is related to lower ABI.¹⁹ This could be explained by the fact that AS (eg, baPWV) reflects the stiffening of central and peripheral muscular arteries,³⁶ which is closely correlated with but different from blood pressure. Central vascular stiffening as a dominant component of baPWV is a strong predictor of cardiovascular

diseases and PAD. In our study, elevated AS was associated with a higher risk for developing PAD regardless of hypertension and blood pressure control status, suggesting that early control of AS could contribute to the prevention of PAD. In contrast, studies have reported the association between blood pressure and PAD development. A large British cohort study including 4.2 million adults aged 30 to 90 years showed that a 20 mm Hg increase in SBP was associated with a 63% increased risk for PAD, while a 10 mm Hg increase in DBP was associated with 35% excess risk.³⁷ Another study involving 12 million people produced consistent results,³⁸ suggesting that lowering blood pressure could reduce the risk for PAD. In this study, we supplemented evidence about

the combined effect of AS and blood pressure on PAD onset and identified people with extremely high risk for PAD.

There are studies focusing on the relationship between blood pressure and AS. A study based on patients with hypertension showed that poorly controlled blood pressure is a risk factor for severe AS.³⁹ Lim et al⁴⁰ showed that changes in blood pressure are associated with corresponding changes in AS parameters. An increase in blood pressure could cause progressive damage to the elasticity of the arterial wall and result in increased stiffness and lead to increased pressure and pulsatile load on the arterial wall, impairment of endothelial function, and atherosclerosis.⁴¹ These findings suggest that blood pressure could interact with AS and then cause severe impairment of vascular lesions, including lower limb arteries. Our study showed that participants with hypertension and concomitant elevated AS had the highest risk for developing PAD.

Pulse-wave velocity is a noninvasive and simple measurement commonly applied in the risk stratification of cardiovascular diseases. Rapid and accurate evaluation of AS facilitates early intervention and control of vascular lesions.⁴² Our findings showed that baPWV could be a risk enhancer of PAD and be potentially used in conjunction with blood pressure. The early control and treatment of AS may prevent the incidence of PAD beyond blood pressure management. Studies have shown that AS is associated with a variety of modifiable factors, such as smoking,⁴³ alcohol consumption,⁴⁴ obesity,⁴⁵ insulin resistance,⁴⁶ and physical activity.⁴⁷ Thus, management of lifestyles and modifiable metabolic risk factors has potential to improve AS.^{48,49} Medications can also be used to improve the stiffness of arterial vessels. Randomized controlled clinical trials have shown that antihypertensive drugs (angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers, and diuretic agents) not only reduce blood pressure but also improve AS in patients with hypertension.⁵⁰ In addition, statins have a protective effect against vascular stiffness, primarily by reducing endothelial dysfunction and improving vascular and myocardial remodeling.^{51,52} Pharmacologic and nonpharmacologic intervention for AS is accompanied by gradual repair of vascular function, which can reduce the incidence of cardiovascular disease, including PAD.

STUDY LIMITATIONS. First, we used ABI to define PAD, and lower limb arterial duplex ultrasound and computed tomographic angiography should be considered in further research. Second, AS was

defined by measuring baPWV alone, and other AS parameters, such as carotid-femoral pulse-wave velocity and peripheral femoral-to-ankle pulse-wave velocity,⁵³ were not collected in this study. Thus, we were unable to compare the results of baPWV and other pulse-wave velocity indexes. Third, this was an observational cohort study, and we could not verify the causal relationship of AS status with incident PAD, which warrants further clinical studies to evaluate the effect of combined control of blood pressure and AS.

CONCLUSIONS

Our study revealed that AS is significantly associated with PAD onset beyond blood pressure, suggesting the clinical importance of combined evaluation and control of AS and blood pressure for the risk stratification and early prevention of PAD.

ACKNOWLEDGMENTS The authors thank all the staff members and participants of the Beijing Health Management Cohort for their invaluable contributions.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This work was funded by the National Natural Science Foundation of China (grants 81872708 and 82073668 to Dr Tao). The funder had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; and in the preparation, review, or approval of the manuscript. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESSES FOR CORRESPONDENCE: Dr Xiuhua Guo, Department of Epidemiology and Health Statistics, School of the Public Health, Capital Medical University, No. 10 Xitoutiao, Youanmen Street, Beijing 100069, China. E-mail: statguo@ccmu.edu.cn. Twitter: [@Stat_Zhiyuan](https://twitter.com/Stat_Zhiyuan). OR Dr Bo Gao, Department of Epidemiology and Health Statistics, School of the Public Health, Capital Medical University, No. 10 Xitoutiao, Youanmen Street, Beijing 100069, China. E-mail: gaobo@ccmu.edu.cn.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: The present study showed that the highest risk for PAD was observed in patients with elevated AS and blood pressure, emphasizing the clinical importance of combined evaluation of AS and blood pressure for the risk stratification and prevention of PAD.

TRANSLATIONAL OUTLOOK: Future clinical studies are needed to evaluate the effect of joint control of AS and blood pressure on cardiovascular outcomes.

REFERENCES

- Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res*. 2015;116(9):1509-1526. <https://doi.org/10.1161/circresaha.116.303849>
- Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet*. 2013;382(9901):1329-1340. [https://doi.org/10.1016/s0140-6736\(13\)61249-0](https://doi.org/10.1016/s0140-6736(13)61249-0)
- Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. *Ultrasound Med Biol*. 1996;22(4):391-398. [https://doi.org/10.1016/0301-5629\(96\)00036-1](https://doi.org/10.1016/0301-5629(96)00036-1)
- Agnelli G, Belch JJF, Baumgartner I, Giovias P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. *Atherosclerosis*. 2020;293:94-100. <https://doi.org/10.1016/j.atherosclerosis.2019.09.012>
- Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2016;51(3):395-403. <https://doi.org/10.1016/j.ejvs.2015.10.022>
- Gonçalves-Martins G, Gil-Sala D, Tello-Díaz C, et al. Prevalence of peripheral arterial disease and associated vascular risk factors in 65-years-old people of northern Barcelona. *J Clin Med*. 2021;10(19):4467. <https://doi.org/10.3390/jcm10194467>
- Sartipy F, Garcia Pereira Filho AJ, Lundin F, Wahlberg E, Sigvant B. Presence of asymptomatic peripheral arterial disease in combination with common risk factors elevates the cardiovascular risk substantially. *Int J Cardiol Cardiovasc Risk Prev*. 2022;13:200130. <https://doi.org/10.1016/j.ijcrp.2022.200130>
- Desormais I, Aboyans V, Guerchet M, et al. Body mass index and peripheral arterial disease, a "U-shaped" relationship in elderly African population—the EPIDEMCA study. *Vasa*. 2020;49(1):50-56. <https://doi.org/10.1024/0301-1526/a000825>
- Martinez-Aguilar E, Orbe J, Fernández-Montero A, et al. Reduced high-density lipoprotein cholesterol: a valuable, independent prognostic marker in peripheral arterial disease. *J Vasc Surg*. 2017;66(5):1527-1533.e1. <https://doi.org/10.1016/j.jvs.2017.04.056>
- Mitchell GF. Arterial stiffness in aging: does it have a place in clinical practice? *Hypertension*. 2021;77(3):768-780. <https://doi.org/10.1161/hypertensionaha.120.14515>
- Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial stiffness and cardiovascular risk in hypertension. *Circ Res*. 2021;128(7):864-886. <https://doi.org/10.1161/circresaha.121.318061>
- Ahmadizar F, Voortman T. Arterial stiffness in childhood: a predictor for later cardiovascular disease? *Eur J Prev Cardiol*. 2018;25(1):100-102. <https://doi.org/10.1177/2047487317743046>
- Zahner GJ, Gruendl MA, Spaulding KA, et al. Association between arterial stiffness and peripheral artery disease as measured by radial artery tonometry. *J Vasc Surg*. 2017;66(5):1518-1526. <https://doi.org/10.1016/j.jvs.2017.06.068>
- Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI. Association of blood pressure measurements with peripheral artery disease events. *Circulation*. 2018;138(17):1805-1814. <https://doi.org/10.1161/circulationaha.118.033348>
- Scandale G, Dimitrov G, Recchia M, et al. Arterial stiffness and 5-year mortality in patients with peripheral arterial disease. *J Hum Hypertens*. 2020;34(7):505-511. <https://doi.org/10.1038/s41371-019-0254-3>
- Tian X, Zuo Y, Chen S, et al. Hypertension, arterial stiffness, and diabetes: a prospective cohort study. *Hypertension*. 2022;79(7):1487-1496. <https://doi.org/10.1161/hypertensionaha.122.19256>
- Wu Z, Jiang Y, Zhou D, et al. Sex-specific association of subclinical hypothyroidism with incident metabolic syndrome: a population-based cohort study. *J Clin Endocrinol Metab*. 2022;107(6):e2365-e2372. <https://doi.org/10.1210/clinem/dgac110>
- Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res*. 2002;25(3):359-364. <https://doi.org/10.1291/hyres.25.359>
- Takahashi T, Tomiyama H, Aboyans V, et al. Association of pulse wave velocity and pressure wave reflection with the ankle-brachial pressure index in Japanese men not suffering from peripheral artery disease. *Atherosclerosis*. 2021;317:29-35. <https://doi.org/10.1016/j.atherosclerosis.2020.11.031>
- Zheng M, Zhang X, Chen S, et al. Arterial stiffness preceding diabetes: a longitudinal study. *Circ Res*. 2020;127(12):1491-1498. <https://doi.org/10.1161/circresaha.120.317950>
- Wu Z, Yu S, Zhang H, et al. Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes. *Cardiovasc Diabetol*. 2022;21(1):262. <https://doi.org/10.1186/s12933-022-01696-1>
- Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. 2011;32(22):2851-2906. <https://doi.org/10.1093/eurheartj/ehr211>
- Wassel CL, Berardi C, Pankow JS, et al. Soluble P-selectin predicts lower extremity peripheral artery disease incidence and change in the ankle brachial index: the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2015;239(2):405-411. <https://doi.org/10.1016/j.atherosclerosis.2015.01.022>
- Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation*. 2007;115(7):928-935. <https://doi.org/10.1161/circulationaha.106.672402>
- Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. *JAMA Intern Med*. 2019;179(7):942-952. <https://doi.org/10.1001/jamainternmed.2019.0600>
- Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. *Nat Rev Cardiol*. 2017;14(3):156-170. <https://doi.org/10.1038/nrcardio.2016.179>
- Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. *Circulation*. 2012;126(24):2890-2909. <https://doi.org/10.1161/CIR.Ob013e318276fbc8>
- Zhang A, Liu Y, Ma S, et al. Effects of ankle-brachial index and brachial-ankle pulse wave velocity on all-cause mortality in a community-based elderly population. *Front Cardiovasc Med*. 2022;9:883651. <https://doi.org/10.3389/fcvm.2022.883651>
- Pereira Filho AJG, Sartipy F, Lundin F, Wahlberg E, Sigvant B. Impact of ankle brachial index calculations on peripheral arterial disease prevalence and as a predictor of cardiovascular risk. *Eur J Vasc Endovasc Surg*. 2022;64(2-3):217-224. <https://doi.org/10.1016/j.ejvs.2022.05.001>
- Mozos I, Malainer C, Horbańczyk J, et al. Inflammatory markers for arterial stiffness in cardiovascular diseases. *Front Immunol*. 2017;8:1058. <https://doi.org/10.3389/fimmu.2017.01058>
- Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014;63(7):636-646. <https://doi.org/10.1016/j.jacc.2013.09.063>
- Kaess BM, Rong J, Larson MG, et al. Aortic stiffness, blood pressure progression, and incident hypertension. *JAMA*. 2012;308(9):875-881. <https://doi.org/10.1001/2012.jama.10503>
- Husmann M, Jacomella V, Thalhammer C, Amann-Vesti BR. Markers of arterial stiffness in peripheral arterial disease. *Vasa*. 2015;44(5):341-348. <https://doi.org/10.1024/0301-1526/a000452>
- Zagura M, Kals J, Kilk K, et al. Metabolomic signature of arterial stiffness in male patients with peripheral arterial disease. *Hypertens Res*. 2015;38(12):840-846. <https://doi.org/10.1038/hr.2015.71>
- Mendes-Pinto D, Rodrigues-Machado MDG. Applications of arterial stiffness markers in peripheral arterial disease. *J Vasc Bras*. 2019;18:e20180093. <https://doi.org/10.1590/1677-5449.009318>
- Wang JW, Zhou ZQ, Hu DY. Prevalence of arterial stiffness in North China, and associations

- with risk factors of cardiovascular disease: a community-based study. *BMC Cardiovasc Disord.* 2012;12:119. <https://doi.org/10.1186/1471-2261-12-119>
37. Emdin CA, Anderson SG, Callender T, et al. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. *BMJ.* 2015;351:h4865. <https://doi.org/10.1136/bmj.h4865>
38. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet.* 2014;383(9932):1899–1911. [https://doi.org/10.1016/s0140-6736\(14\)60685-1](https://doi.org/10.1016/s0140-6736(14)60685-1)
39. Qu G, Zhang Z, Zhu H. Association Between blood pressure control and arterial stiffness in middle-aged and elderly Chinese patients with hypertension. *Med Sci Monit.* 2021;27:e931414. <https://doi.org/10.12659/msm.931414>
40. Lim J, Pearman ME, Park W, Alkatan M, Machin DR, Tanaka H. Impact of blood pressure perturbations on arterial stiffness. *Am J Physiol Regul Integr Comp Physiol.* 2015;309(12):R1540–R1545. <https://doi.org/10.1152/ajpregu.00368.2015>
41. Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiological mechanisms and emerging clinical indications. *Vascul Pharmacol.* 2016;77:1–7. <https://doi.org/10.1016/j.vph.2015.11.083>
42. Milan A, Zocaro G, Leone D, et al. Current assessment of pulse wave velocity: comprehensive review of validation studies. *J Hypertens.* 2019;37(8):1547–1557. <https://doi.org/10.1097/hjh.0000000000002081>
43. Inomoto A, Deguchi J, Fukuda R, et al. Cohabiting with smokers is an independent factor for worsening arterial stiffness even in smoking workers. *J UOEH.* 2020;42(3):251–259. <https://doi.org/10.7888/juoeh.42.251>
44. Nishiwaki M, Yamaguchi T, Nishida R, Matsumoto N. Dose of alcohol from beer required for acute reduction in arterial stiffness. *Front Physiol.* 2020;11:1033. <https://doi.org/10.3389/fphys.2020.01033>
45. Kim HL, Ahn DW, Kim SH, et al. Association between body fat parameters and arterial stiffness. *Sci Rep.* 2021;11(1):20536. <https://doi.org/10.1038/s41598-021-00175-z>
46. Wu Z, Zhou D, Liu Y, et al. Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population. *Cardiovasc Diabetol.* 2021;20(1):134. <https://doi.org/10.1186/s12933-021-01330-6>
47. Caverro-Redondo I, Tudor-Locke C, Álvarez-Bueno C, Cunha PG, Aguiar EJ, Martínez-Vizcaíno V. Steps per day and arterial stiffness. *Hypertension.* 2019;73(2):350–363. <https://doi.org/10.1161/hypertensionaha.118.11987>
48. Jennings A, Berendsen AM, de Groot L, et al. Mediterranean-style diet improves systolic blood pressure and arterial stiffness in older adults. *Hypertension.* 2019;73(3):578–586. <https://doi.org/10.1161/hypertensionaha.118.12259>
49. Vamvakis A, Gkaliagkousi E, Lazaridis A, et al. Impact of intensive lifestyle treatment (diet plus exercise) on endothelial and vascular function, arterial stiffness and blood pressure in stage 1 hypertension: results of the HINTreat randomized controlled trial. *Nutrients.* 2020;12(5):1326. <https://doi.org/10.3390/nu12051326>
50. Ong KT, Delorme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. *J Hypertens.* 2011;29(6):1034–1042. <https://doi.org/10.1097/HJH.0b013e328346a583>
51. Alidadi M, Montecucco F, Jamialahmadi T, Al-Rasadi K, Johnston TP, Sahebkar A. Beneficial effect of statin therapy on arterial stiffness. *Biomed Res Int.* 2021;2021:5548310. <https://doi.org/10.1155/2021/5548310>
52. Sahebkar A, Pećin I, Tedeschi-Reiner E, Derosa G, Maffioli P, Reiner Ž. Effects of statin therapy on augmentation index as a measure of arterial stiffness: a systematic review and meta-analysis. *Int J Cardiol.* 2016;212:160–168. <https://doi.org/10.1016/j.ijcard.2016.03.010>
53. Stone K, Fryer S, Kelsch E, et al. Validity and reliability of lower-limb pulse-wave velocity assessments using an oscillometric technique. *Exp Physiol.* 2019;104(5):765–774. <https://doi.org/10.1113/ep087444>

KEY WORDS arterial stiffness, blood pressure, brachial-ankle pulse-wave velocity, hypertension, peripheral arterial disease

APPENDIX For supplemental tables and figures and the standard questionnaire, please see the online version of this paper.